Learn about a phase II multi-center study evaluating combination immunotherapy for advanced cholangiocarcinoma (bile duct cancer) with pembrolizumab and Sylatron (peginterferon alfa-2b): HCRN GI16-263. https://hoosiercancer.org/clinical-tr...